文献速递白血病造血干细胞移植与细胞治疗

长效聚乙二醇干扰素γ增强供者T细胞对AML细胞的杀伤

Long-acting pegylated interferon gamma sensitizes AML cells to killing by donor T cells.
PubMed 文献 · Blood Adv · 2026-01-01

异基因造血干细胞移植后AML复发与白血病细胞MHC-II表达丢失相关。单细胞测序显示MHC-II低表达AML细胞中I/II型干扰素及TNF-α通路下调;外源IFN-γ可恢复MHC-II表达并增强供者T细胞同种反应性。小鼠模型中长效聚乙二醇干扰素γ耐受良好,较重组IFN-γ更显著上调MHC-II并增强供者T细胞对AML细胞的清除。

要点

  • 移植后复发AML细胞MHC-II低表达伴干扰素和TNF-α通路下调
  • 外源IFN-γ而非IFN-α或TNF-α可恢复MHC-II表达
  • 长效聚乙二醇干扰素γ在小鼠中增强供者T细胞清除AML细胞

核心结论

  • 外源长效IFN-γ可能通过上调MHC-II使移植后复发AML细胞对供者T细胞杀伤更敏感,具有治疗潜力。

研究设计与样本

  • 对MHC-II丢失的患者样本行单细胞RNA测序,比较同一标本中MHC-II低与高表达AML细胞。
  • 体外用IFN-γ、IFN-α或TNF-α处理移植后复发细胞及THP1细胞,检测MHC-II表达与供者T细胞同种反应性。
  • 在健康小鼠和异种移植模型中测试长效聚乙二醇干扰素γ的耐受性及增强供者T细胞清除AML细胞的效果。

主要发现

  • MHC-II低表达AML细胞较同一标本MHC-II高表达细胞下调I/II型干扰素及TNF-α炎症信号通路。
  • IFN-γ而非IFN-α或TNF-α可恢复移植后复发MHC-II低表达细胞的MHC-II表达。
  • IFN-γ处理THP1细胞可增强HLA不合供者T细胞的体外同种反应性。
  • 长效聚乙二醇干扰素γ在健康小鼠中耐受良好,较重组IFN-γ更显著上调MHC-II表达。
  • 长效聚乙二醇干扰素γ预处理在异种移植中增强供者T细胞对AML细胞的清除。

临床怎么用

  • 移植后复发且AML细胞MHC-II低表达的患者,可考虑外源长效IFN-γ增敏供者T细胞杀伤的策略。

局限性

  • 机制与疗效证据主要来自体外实验和小鼠模型,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with the loss of major histocompatibility complex class II (MHC-II) expression on AML cells. Although the mechanisms by which this occurs are unknown, the loss of antigen presentation by MHC-II may contribute to AML relapse after transplantation. In this study, we performed single-cell RNA sequencing on patient samples with MHC-II loss and observed downregulation of inflammatory signaling pathways, including type I and II interferons and tumor necrosis factor alpha (TNF-α), in MHC-II-low AML cells compared with MHC-II-high AML cells from the same samples. Treatment with exogenous interferon gamma (IFN-γ) but not IFN-α or TNF-α restored MHC-II expression in MHC-II-low post-HSCT relapse cells, and IFN-γ treatment of THP1 cells increased alloreactivity of HLA-mismatched donor T cells in vitro. Because recombinant IFN-γ has a short half-life in vivo, we tested whether a novel, long-acting pegylated IFN-γ (peg-IFN-γ) could increase the sensitivity of AML cells to donor T-cell clearance in mouse models. Peg-IFN-γ treatment was well tolerated in healthy mice and led to more robust upregulation of MHC-II expression compared with recombinant IFN-γ. In addition, pretreatment with peg-IFN-γ enhanced AML cell clearance by donor T cells in xenografts, raising the possibility that sensitization of AML cells by exogenous long-acting IFN-γ may be of therapeutic benefit in patients with AML relapsing after HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Basu V, Mannino G, Mpofu L, et al. Long-acting pegylated interferon gamma sensitizes AML cells to killing by donor T cells. Blood Adv. 2026. PMID: 42480219. doi:10.1182/bloodadvances.2026019670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。